TGF-beta-Smad2/3 signaling inhibitors (Yale University)

N/A

Report date: 2025/03/19 20:00:56

NME

Base Information

Drug NameTGF-beta-Smad2/3 signaling inhibitors (Yale University)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionMothers against decapentaplegic homolog 3 inhibitorsTransforming growth factor beta receptors antagonistsMothers against decapentaplegic homolog 2 inhibitors

TargetsMothers against decapentaplegic homolog 2Transforming growth factor beta receptorsMothers against decapentaplegic homolog 3

Therapy Area/IndicationsAlzheimer Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesYale University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesYale University

Active IndicationsN/A

Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A